Transungual drug delivery: Current status

International Journal of Pharmaceutics

Volumn 384, Issue 1-2, 2010, Pages 1-8

  Elkeeb, Rania ^a   AliKhan, Ali ^b   Elkeeb, Laila ^c   Hui, Xiaoying ^a   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antifungal; Nail penetration; Onychomycosis; Onychopharmacokinetics; Ungual drug delivery

Indexed keywords

2 NONYL 1,3 DIOXOLANE; 5 FLUORO 1,3 DIHYDRO 2,1 BENZOXABOROL 1 OL; ACETYLCYSTEINE; AMINOLEVULINIC ACID; AMOROLFINE; AMPHOTERICIN B; CICLOPIROX; CICLOPIROXOLAMINE; ECONAZOLE; FLUOCINOLONE ACETONIDE; GRISEOFULVIN; ITRACONAZOLE; KERATINASE; KETOCONAZOLE; MERCAPTOETHANOL; METFORMIN; MICONAZOLE; OXICONAZOLE; PAPAIN; PLACEBO; SALICYLIC ACID; SERTACONAZOLE; TERBINAFINE; THIOGLYCOLIC ACID; TIOPRONIN; TOLNAFTATE; UREA;

ABRASION; ANTIFUNGAL ACTIVITY; AVULSION INJURY; CARBON DIOXIDE LASER; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; ELECTROOSMOSIS; FINGER NAIL; HOOF AND CLAW; HUMAN; HYDRATION; IONIC STRENGTH; IONTOPHORESIS; MINIMUM INHIBITORY CONCENTRATION; NAIL DYSTROPHY; NONHUMAN; ONYCHOMYCOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION; ULTRASOUND; ULTRAVIOLET RADIATION;

ANIMALS; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NAIL DISEASES; NAILS;

EID: 70649115369     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.002     Document Type: Review

References (55)

1. Baden H.P. Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch. Dermatol. 130 (1994) 558-559
2. Baden H.P., Goldsmith L.A., and Fleming B. A comparative study of the physicochemical properties of human keratinized tissues. Biochim. Biophys. Acta 322 (1973) 269-278
3. Baran R., Hay R.J., and Garduno J.I. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J. Dermatolog. Treat. 19 (2008) 72-81
4. Baran R., and Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. Venereol. 19 (2005) 21-29
5. Behl P.N. Abrasion in the treatment of nail disorders. Indian J. Dermatol. 18 (1973) 77-79
6. Bronaugh R.L., and Maibach H.I. Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methodology (2005), Taylor & Francis, Boca Raton
7. Brown M.B., Khengar R.H., Turner R.B., Forbes B., Traynor M.J., Evans C.R., and Jones S.A. Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement. Int. J. Pharm. 370 (2009) 61-67
8. Chen L.J., Meng Q.F., Chen Y.M., Smales R.J., and Yip K.H. Effect of fluoride iontophoresis on the microtensile bond strength between dentin and two adhesive systems. J. Dent. 36 (2008) 697-702
9. Crawford, F., Hollis, S., 2007. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst. Rev. (3): CD001434. doi:10.1002/14651858.CD001434.pub2.
10. De Berker D., Mawhinney B., and Sviland L. Quantification of regional matrix nail production. Br. J. Dermatol. 134 (1996) 1083-1086
11. Di Chiacchio N., Kadunc B.V., De Almeida A.R., and Madeira C.L. Nail abrasion. J. Cosmet. Dermatol. 2 (2003) 150-152
12. Donnelly R.F., Mccarron P.A., Lightowler J.M., and Woolfson A.D. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J. Control. Release 103 (2005) 381-392
13. Effendy I., Lecha M., Feuilhade De Chauvin M., Di Chiacchio N., and Baran R. Epidemiology and clinical classification of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 19 (2005) 8-12
14. Elewski B.E., and Hay R.J. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin. Infect. Dis. 23 (1996) 305-313
15. Gradisar H., Friedrich J., Krizaj I., and Jerala R. Similarities and specificities of fungal keratinolytic proteases: comparison of keratinases of Paecilomyces marquandii and Doratomyces microsporus to some known proteases. Appl. Environ. Microbiol. 71 (2005) 3420-3426
16. Grover C., Bansal S., Nanda S., Reddy B.S., and Kumar V. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br. J. Dermatol. 157 (2007) 364-368
17. Gunt H., and Kasting G.B. Hydration effect on human nail permeability. J. Cosmet. Sci. 57 (2006) 183-184
18. Gunt H.B., and Kasting G.B. Effect of hydration on the permeation of ketoconazole through human nail plate in vitro. Eur. J. Pharm. Sci. 32 (2007) 254-260
19. Gupta A.K., Fleckman P., and Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 43 (2000) S70-80
20. Gupta A.K., and Scher R.K. Oral antifungal agents for onychomycosis. Lancet 351 (1998) 541-542
21. Hao J., and Li S.K. Mechanistic study of electroosmotic transport across hydrated nail plates: effects of pH and ionic strength. J. Pharm. Sci. 97 (2008) 5186-5197
22. Hao J., and Li S.K. Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis. J. Pharm. Sci. 97 (2008) 893-905
23. Haria M., and Bryson H.M. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49 (1995) 103-120
24. Hettinger D.F., and Valinsky M.S. Treatment of onychomycosis with nail avulsion and topical ketoconazole. J. Am. Podiatr. Med. Assoc. 81 (1991) 28-32
25. Hoogdalem E.J., Hoven W.E., Terpstra I.J., Zijtveld J., Verschoor J.S.C., and Visser J.N. Nail penetration of the antifungal agent oxiconazole after repeated topical application in healthy volunteers, and the effect of acetylcysteine. Eur. J. Pharm. Sci. 5 (1997) 119-127
26. Horwath-Winter J., Schmut O., Haller-Schober E.M., Gruber A., and Rieger G. Iodide iontophoresis as a treatment for dry eye syndrome. Br. J. Ophthalmol. 89 (2005) 40-44
27. Hui X., Baker S.J., Wester R.C., Barbadillo S., Cashmore A.K., Sanders V., Hold K.M., Akama T., Zhang Y.K., Plattner J.J., and Maibach H.I. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J. Pharm. Sci. 96 (2007) 2622-2631
28. Hui X., Chan T.C., Barbadillo S., Lee C., Maibach H.I., and Wester R.C. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J. Pharm. Sci. 92 (2003) 142-148
29. Hui X., Wester R.C., Barbadillo S., Lee C., Patel B., Wortzmman M., Gans E.H., and Maibach H.I. Ciclopirox delivery into the human nail plate. J. Pharm. Sci. 93 (2004) 2545-2548
30. Karrell M.L. Laser Apparatus for Making Holes and Etchings (1999), USPTO, USA
31. Kassan D.G., Lynch A.M., and Stiller M.J. Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. J. Am. Acad. Dermatol. 34 4 (1996) 657-666
32. Kasting G.B., and Barai N.D. Equilibrium water sorption in human stratum corneum. J. Pharm. Sci. 92 (2003) 1624-1631
33. Kasting G.B., Barai N.D., Wang T.F., and Nitsche J.M. Mobility of water in human stratum corneum. J. Pharm. Sci. 92 (2003) 2326-2340
34. Khengar R.H., Jones S.A., Turner R.B., Forbes B., and Brown M.B. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm. Res. 24 (2007) 2207-2212
35. Kobayashi Y., Miyamoto M., Sugibayashi K., and Morimoto Y. Enhancing effect of N-acetyl-l-cysteine or 2-mercaptoethanol on the in vitro permeation of 5-fluorouracil or tolnaftate through the human nail plate. Chem. Pharm. Bull. (Tokyo) 46 (1998) 1797-1802
36. Malhotra G.G., and Zatz J.L. Investigation of nail permeation enhancement by chemical modification using water as a probe. J. Pharm. Sci. 91 (2002) 312-323
37. Maltezos G., and Scherer A. Treatment of Toenail Fungus (2005), USPTO, USA
38. Mertin D., and Lippold B.C. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy. J. Pharm. Pharmacol. 49 (1997) 866-872
39. Mididoddi P.K., Prodduturi S., and Repka M.A. Influence of tartaric acid on the bioadhesion and mechanical properties of hot-melt extruded hydroxypropyl cellulose films for the human nail. Drug Dev. Ind. Pharm. 32 (2006) 1059-1066
40. Mohorcic M., Torkar A., Friedrich J., Kristl J., and Murdan S. An investigation into keratinolytic enzymes to enhance ungual drug delivery. Int. J. Pharm. 332 (2007) 196-201
41. Monti D., Saccomani L., Chetoni P., Burgalassi S., Saettone M.F., and Mailland F. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev. Ind. Pharm. 31 (2005) 11-17
42. Murdan S. 1st meeting on topical drug delivery to the nail. Expert. Opin. Drug Deliv. 4 (2007) 453-455
43. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert. Opin. Drug Deliv. 5 (2008) 1267-1282
44. Murthy S.N., Waddell D.C., Shivakumar H.N., Balaji A., and Bowers C.P. Iontophoretic permselective property of human nail. J. Dermatol. Sci. 46 (2007) 150-152
45. Murthy S.N., Wiskirchen D.E., and Bowers C.P. Iontophoretic drug delivery across human nail. J. Pharm. Sci. 96 (2007) 305-311
46. Myoung Y., and Choi H.K. Permeation of ciclopirox across porcine hoof membrane: effect of pressure sensitive adhesives and vehicles. Eur. J. Pharm. Sci. 20 (2003) 319-325
47. Nowicki K.D., Hummer III C.D., Heidt Jr. R.S., and Colosimo A.J. Effects of iontophoretic versus injection administration of dexamethasone. Med. Sci. Sports Exerc. 34 (2002) 1294-1301
48. Quintanar-Guerrero D., Ganem-Quintanar A., Tapia-Olguin P., Kalia Y.N., and Buri P. The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev. Ind. Pharm. 24 (1998) 685-690
49. Repka M.A., Mididoddi P.K., and Stodghill S.P. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int. J. Pharm. 282 (2004) 95-106
50. Repka M.A., O'haver J., See C.H., Gutta K., and Munjal M. Nail morphology studies as assessments for onychomycosis treatment modalities. Int. J. Pharm. 245 (2002) 25-36
51. Rothermel E., and Apfelberg D.B. Carbon dioxide laser use for certain diseases of the toenails. Clin. Podiatr. Med. Surg. 4 (1987) 809-821
52. Susilo R., Korting H.C., Greb W., and Strauss U.P. Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am. J. Clin. Dermatol. 7 (2006) 259-262
53. Tom C.M., and Kane M.P. Management of toenail onychomycosis. Am. J. Health Syst. Pharm. 56 (1999) 865-871
54. Walters K.A., Flynn G.L., and Marvel J.R. Physicochemical characterization of the human nail: solvent effects on the permeation of homologous alcohols. J. Pharm. Pharmacol. 37 (1985) 771-775
55. Zaug M., and Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin. Exp. Dermatol. 17 (1992) 61-70